The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Yesterday, the UK’s Chancellor Rishi Sunak delivered a Budget that aimed to be fiscally disciplined following the economic turmoil caused by the pandemic, as well optimistic in setting out extra public spending to support the post-COVID economy. 28 October 2021
Shares of US pharma major Bristol Myers Squibb closed down 3% at $56.49 yesterday, after the company reported results for the third quarter of 2021, which it said reflect solid sales, strong commercial execution and continued progress of the company’s pipeline. 28 October 2021
Vifor Pharma was trading 5% lower at the end of trading on Wednesday while its partner Angion Biomedica lost more than 50% of its market value in the first half of the day’s trading in New York. 27 October 2021
UK drugmaker GlaxoSmithKline reported sales for the third quarter of £9.08 billion ($12.47), an increase of 5% on the same period in 2020 and ahead of the £8.7 billion predicted by analysts. 27 October 2021
Japan’s leading drugmaker Takeda Pharmaceutical today said it is exercising its option to acquire UK-based GammaDelta Therapeutics, an Abingworth portfolio company, focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. 27 October 2021
Shares of Israel’s Teva Pharmaceutical Industries were down almost 5% at 2,975 shekels today, after it reported results for the quarter ended September 30, 2021, which was below the analysts' consensus on both revenue and profit. 27 October 2021
Privately-held German pharma major Boehringer Ingelheim and Austria’s Thoeris have announced a collaboration and license deal aimed at investigating new first-in-class therapies for patients with urea cycle disorders (UCDs). 27 October 2021
In October 2016, Gabriel Baertschi left his role as president and general manager of AstraZeneca in Japan to take the top job at Germany’s Grünenthal Group. 27 October 2021
Non-profit organization the Medicines Patent Pool (MPP) and MSD, the ex-North America name of Merck & Co, have signed a voluntary licensing agreement to facilitate affordable global access for molnupiravir, an investigational oral COVID-19 antiviral medicine developed by the US pharma giant. 27 October 2021
The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted 17 to 0, with 1 abstention, to recommend that the FDA grant Emergency Use Authorization (EUA) for Comirnaty, the COVID-19 vaccine from Pfizer and BioNTech, in children five to 27 October 2021
Having risen nearly 50% over the last six month to $57.68, US biotech Cortexyme saw its shares tank 72% to $16.18 in after-hours trading yesterday, after it revealed that its investigational oral Alzheimer’s candidate failed to achieve a clinical goal. 27 October 2021
Israel’s Teva Pharmaceutical Industries and German drug developer MODAG GmbH have signed an exclusive worldwide licensing and development agreement for MODAG's lead compound anle138b and a related compound, sery433. 27 October 2021
Sanofi and Regeneron have shared results from a second Phase III trial assessing the investigational use of Dupixent (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). 26 October 2021
Now three years since its founding, US biotech Mammoth Biosciences, which is building the next generation of CRISPR products to cure and detect disease, has signed its first major R&D deal. 26 October 2021
US a multi-asset longevity biotech Cambrian Biopharma today announced the closing of an oversubscribed Series C financing, which raised $100 million. 26 October 2021
After years of questions about the future of its generics and biosimilars business Sandoz, Swiss pharma giant Novartis has finally announced a strategic review of the unit. 26 October 2021
US pharma major Eli Lilly today reported third-quarter 2021 financial results that did not live up to all analysts’ earnings hopes, despite better-than-expected top-line growth, sending the firm’s shares down 1.9% to $240.31 in early trading. 26 October 2021
UK-based biotech Bicycle Therapeutics today announced that Swiss pharma giant Roche’s subsidiary Genentech has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. 26 October 2021
US mRNA specialist Moderna has announced positive interim data from a Phase II/III study of the company’s vaccine against COVID-19, in children aged six to under 12 years of age. 26 October 2021
Paul Domenet, partner and communications creative director at Free The Birds, offers an Expert View on how big pharma can improve its image. 26 October 2021